Watch: Biotech Going Up Against Big Pharma

As co-founder, chairman & chief executive of Ocugen, Shankar Musunuri, is looking to bring eye disease products to the patients that big pharma’s drugs have left out. The Malvern, Penn.-based company has four compounds in its pipeline at various stages of development. It’s most advanced candidate, OCU300, is gearing up for Phase III trials in 2018. It’s second candidate, OCU310, combines brimonidine, a drug usually designed for patients with glaucoma, and a steroid. With some of Ocugen’s products, like it’s OCU100 compound designed to delay the progression of retinitis pigmentosa, there is no other drug currently on the market – so there’s no immediate competition. “The goal is to get something to the market to help patients as soon as possible because they don’t have anything today,”

Follow us on social media for the latest updates in B2B!

Image

Latest

Nightingales Summit: Empowering the Next Generation of Nigerian Nurses
Nightingales Summit: Empowering the Next Generation of Nigerian Nurses
April 2, 2026

In this episode of Care Anywhere, host Lea Sims sits down with Nigerian nurse entrepreneur and advocate Obafemi Arowosegbe to discuss leadership, mentorship, and the future of nursing in Africa. While still a nursing student, Obafemi founded the Nightingale Summit, a growing conference designed to empower nursing students and early-career nurses with leadership skills,…

Read More
Oncology
From Denial to Access: Rethinking Oncology Care Through AI, Clinical Trials, and Patient-Centered Innovation
April 1, 2026

The rapid expansion of precision medicine, biologics, and targeted cancer therapies is transforming oncology—but it’s also overwhelming a system not built to keep pace. In the U.S., cancer drugs now account for some of the highest-cost treatments in healthcare, and with that has come a surge in prior authorization requirements and denials. Studies suggest physicians…

Read More
Firefly
Pursuing the Impossible: The New Space Race with Firefly Aerospace Co-Founder Eric Salwan
April 1, 2026

Many companies set out to do something hard. Firefly Aerospace set out to do the impossible. After 10 years and several existential moments, Firefly did what no private company ever had: in 2025, it successfully landed on the Moon. Before Firefly, only countries had ever landed on the Moon—and it took extraordinary national effort…

Read More
internship
Tale of Two Interns: What AI Is Really Doing to Entry-Level Work
March 30, 2026

The narrative around early-career work has become increasingly pessimistic, with headlines pointing to a shrinking pool of entry-level roles, fewer internship opportunities, and AI accelerating both trends. But beneath that narrative, a different tension is emerging—one that’s less about the disappearance of opportunity and more about how it’s being reshaped. Students are using AI…

Read More